ClinicalTrials.gg
CompletedNCT05637255Updated Apr 13, 2026

A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)

A Phase 2 interventional study of SYL1801 in Wet Macular Degeneration, Neovascular Age-related Macular Degeneration and Macular Degeneration, sponsored by Sylentis, S.A.. Completed at 16 sites in 3 countries. Open to participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Sylentis, S.A. (part of PharmaMar) · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
99
Allocation
Randomized
Ages
50 Years to 85 Years
Sex
All
01

Study summary

The goal of this clinical trial is to compare the safety and effect on visual acuity of three different doses of SYL1801 eye drops.

02

Conditions studied

  • Wet Macular Degeneration
  • Neovascular Age-related Macular Degeneration
  • Macular Degeneration

Keywords

  • siRNA
  • oligonucleotide
03

In context

Wet Macular Degeneration

93 studies on the registry are indexed under Wet Macular Degeneration; 10 are open to participants now.

This study's enrollment of 99 is close to the median of 101 across 74 interventional studies indexed under Wet Macular Degeneration.

Browse Wet Macular Degeneration studies →

Lead sponsor

Sylentis, S.A. is the lead sponsor of 12 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed
  • Active subfoveal or juxtafoveal choroidal neovascularization secondary to AMD
  • Best Corrected Visual Acuity (BCVA) between 70-25 letters (ETDRS) at Screening
  • Intraretinal or subretinal fluid
  • Central Subfield Thickness > 300 µm

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breastfeeding females or those with a positive pregnancy test.
  • Females of who will not use a medically acceptable method
  • Current, previous chronic or recurrent condition according to the investigator's judgement.
  • Concomitant treatment or prior ocular procedure or surgery, or alteration of the dose of systemic medications
  • Concurrent disease in the study eye
  • Previous treatment with systemic anti-Vascular Endothelial Growing Factor (Anti-VEGF) drugs or pro-VEGF treatments
  • Concurrent disease in the study eye, other than AMD
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
99 participants (actual)

Study arms

  • Experimental
    SYL1801 ophthalmic solution Low Dose once daily

    42 treatment days

    Drug: SYL1801

  • Experimental
    SYL1801 ophthalmic solution Middle Dose once daily

    42 treatment days

    Drug: SYL1801

  • Experimental
    SYL1801 ophthalmic solution High Dose once daily

    42 treatment days

    Drug: SYL1801

Interventions

  • DrugSYL1801

    1 drop in the eligible eye

06

What researchers measure

Primary outcomes

  1. Change from Baseline on visual acuity on Day 42 after last instillation of the assigned dose level

    ETDRS chart

    Time frame: 42 days after first administration

Secondary outcomes

  1. Proportion of subjects within each cohort who maintained visual acuity on Day 42 after last instillation of the assigned dose level

    ETDRS chart

    Time frame: 42 days after first administration

  2. Proportion of subjects within each cohort who gained visual acuity on Day 42 after last instillation of the assigned dose level

    ETDRS chart

    Time frame: Through study completion, up to 42 days

  3. Proportion of subjects within each cohort who needed rescue medication at any point of the study

    Time frame: Through study completion, up to 42 days

  4. Change from Baseline on flow area on Day 42 after last instillation of the assigned

    Optical Coherence Tomography Angiography (OCTA)

    Time frame: 42 days after first administration

  5. Change from Screening on leakage area on Day 42 after last instillation of the assigned

    Fluorescein Angiography

    Time frame: 43 days after first administration

  6. Change from Baseline on intraocular pressure (IOP)

    Tonometry

    Time frame: 42 days after first administration

  7. Adverse Event Evaluation

    Time frame: Through study completion, up to 42 days

07

Study locations

16 sites
  • SYL1801 Investigative Site
    Brno, 62500, Czechia
  • SYL1801 Investigative Site
    Chomutov, 43001, Czechia
  • SYL1801 Investigative Site
    Frýdek-Místek, 738 01, Czechia
  • SYL1801 Investigative Site
    Kyjov, 69701, Czechia
  • SYL1801 Investigative Site
    Liberec, 46063, Czechia
  • SYL1801 Investigative Site
    Ostrava, 70200, Czechia
  • SYL1801 Investigative Site
    Prague, 14000, Czechia
  • SYL1801 Investigative Site
    Prague, 17000, Czechia
  • SYL1801 Investigative Site
    Gdansk, 80-809, Poland
  • SYL1801 Investigative Site
    Krakow, 31-070, Poland
  • SYL1801 Investigative Site
    Rzeszów, 35-017, Poland
  • SYL1801 Investigative Site
    Warsaw, 01-258, Poland
  • SYL1801 Investigative Site
    Bratislava, 85107, Slovakia
  • SYL1801 Investigative Site
    Košice, 04011, Slovakia
  • SYL1801 Investigative Site
    Poprad, 05801, Slovakia
  • SYL1801 Investigative Site
    Žilina, Slovakia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2022 to primary completion in Dec 2024, 24 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 16, 2022
First posted
Dec 5, 2022
StartActual
Nov 22, 2022
Primary completionActual
Dec 19, 2024
CompletionActual
Dec 19, 2024
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05637255
Lead sponsor
Sylentis, S.A.
Responsible party
Sponsor
First posted
Dec 5, 2022
Start date
Nov 22, 2022
Primary completion
Dec 19, 2024
Completion
Dec 19, 2024
Last update
Apr 13, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion